Pd26-05 Application of the Stratified Cancer Surveillance Criteria to the Michigan Urologic Surgery Improvement Collaborative Active Surveillance Cohort: A Step Towards Risk Stratified Active Surveillance

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance II (PD26)1 May 2024PD26-05 APPLICATION OF THE STRATIFIED CANCER SURVEILLANCE CRITERIA TO THE MICHIGAN UROLOGIC SURGERY IMPROVEMENT COLLABORATIVE ACTIVE SURVEILLANCE COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE Michael Wang, Jack R. Vercnocke, Stephanie Diagnault-Newton, Corinne Labardee, Alice Semerjian, Tudor Borza, Vincent Gnanapragasam, Kevin Ginsburg, and For the Michigan Urological Surgery Improvement Collaborative Michael WangMichael Wang , Jack R. VercnockeJack R. Vercnocke , Stephanie Diagnault-NewtonStephanie Diagnault-Newton , Corinne LabardeeCorinne Labardee , Alice SemerjianAlice Semerjian , Tudor BorzaTudor Borza , Vincent GnanapragasamVincent Gnanapragasam , Kevin GinsburgKevin Ginsburg , and For the Michigan Urological Surgery Improvement Collaborative View All Author Informationhttps://doi.org/10.1097/01.JU.0001008556.20565.76.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The STRATified CANcer Surveillance (STRATCANS) criteria were developed to risk stratify patients on active surveillance (AS) and prospectively tailor the intensity of surveillance testing according to their risk of biopsy upgrading. We tested applicability of the STRATCANS criteria to a diverse AS population, the Michigan Urologic Surgery Improvement Collaborative Active Surveillance (MUSIC) AS cohort. METHODS: We reviewed the MUSIC AS cohort for men diagnosed with Cambridge Prognostic Group (CPG) 1 (GG1 and PSA <10ng/mL and cT stage 1-2) and CPG 2 (GG1 and PSA 10-20 ng/mL and cT Stage 1-2 or GG2 and PSA<10 ng/mL and cT stage 1-2) PC diagnosed from 2016 to 2022. Men were group by STRATCANS criteria (STRATCANS 1: CPG 1 and PSA density (PSAD) <0.15; STRATCANS 2: CPG2 and PSAD<0.15 or CPG 1 and PSAD≥0.15; STRATCANS 3: CPG 2 and PSAD≥0.15). The primary outcomes were time to biopsy upgrading to CPG 3 (GG3), any biopsy upgrading, and time on AS. Kaplan-Meier methods and log-rank tests were used to assess time-to-event outcomes. RESULTS: 7,578 men with CPG 1 (5,862) and CPG 2 (1,716) PC, were classified into STRATCANS 1 (4,009) STRATCANS 2 (2,732) and STRATCANS 3 (837). 3,981 men with a surveillance biopsy were included in the biopsy upgrading outcome (STRATCANS 1: 2,163; STRATCANS 2: 1,428; STRATCANS 3: 390). Biopsy upgrading to ≥CPG 3 (Figure 1, p<0.001) and any biopsy upgrading (p<0.001) were significantly different between STRATCANS groups. Probability of upgrading to ≥CPG3 within 3 years of diagnosis was 13%, 33%, and 53% for STRATCANS 1, 2, and 3, respectively. STRATCANS criteria was associated with duration on AS (Figure 2, p<0.001), with 24%, 42% and 46% for STRATCANS 1, 2, and 3 undergoing treatment within 5 years, respectively. CONCLUSIONS: The STRATCANS criteria was associated with the risk of biopsy upgrading and treatment-free survival for men on AS in MUSIC. These data support the use of the STRATCANS criteria to risk stratify the intensity of active surveillance monitoring. Download PPTDownload PPT Source of Funding: Funding from Blue Cross Blue Shield of Michigan © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e545 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Michael Wang More articles by this author Jack R. Vercnocke More articles by this author Stephanie Diagnault-Newton More articles by this author Corinne Labardee More articles by this author Alice Semerjian More articles by this author Tudor Borza More articles by this author Vincent Gnanapragasam More articles by this author Kevin Ginsburg More articles by this author For the Michigan Urological Surgery Improvement Collaborative More articles by this author Expand All Advertisement PDF downloadLoading ...